COVID-19 hasn’t disappeared, but as of late April 2026, viral activity in the United States is at its lowest possible level. CDC wastewater surveillance, which tracks viral particles in sewage as a proxy for how much virus is circulating, rates current COVID-19 activity as “Very Low.” That doesn’t mean the virus is gone. It means the country is in a trough between waves, and the pattern over recent years suggests another rise is likely at some point.
What the Seasonal Pattern Looks Like Now
COVID-19 has settled into a roughly predictable rhythm over the past few years, though it’s less tidy than the flu’s annual winter peak. In each of the past three years, the U.S. has experienced two COVID waves: one in summer and one in winter. Winter hospitalizations typically peak in late December or early January, while the summer wave tends to build through June and July.
That two-wave pattern is the best guide for what to expect. The CDC notes it’s still difficult to predict the exact magnitude or timing of each wave, and COVID peaks don’t always line up neatly with flu or RSV seasons. But the days of completely unpredictable surges appear to be over. If recent history holds, the next noticeable uptick would likely come during summer 2026.
Variants Still Circulating
The virus continues to mutate, though no current variant has triggered the kind of alarm that delta or early omicron did. The World Health Organization lists JN.1 as a variant of interest, with several sublineages under monitoring, including KP.3.1.1, NB.1.8.1, and XFG. These are all descendants of the omicron family and tend to cause similar illness. None has shown signs of dramatically increased severity compared to earlier omicron strains.
New variants can drive a wave simply by being different enough from previous strains to partially evade existing immunity, not because they’re more dangerous. That’s why waves keep happening even though most people have some immunity from infection, vaccination, or both.
Symptoms With Current Strains
The symptom profile hasn’t changed dramatically. Fever, chills, cough, and fatigue remain the most common complaints. Loss of taste or smell, which was a hallmark of earlier strains, still shows up but is far less frequent than it was in 2020 and 2021. The CDC notes that symptoms can vary depending on which variant you catch and your vaccination status, but for most people, current COVID infections resemble a moderate cold or flu that resolves within a week or two.
Long COVID Risk Has Dropped
One of the more encouraging developments is a significant decline in long COVID risk over the course of the pandemic. A large study from Washington University School of Medicine, tracking over 441,000 infected veterans and 4.7 million uninfected controls, found that long COVID rates fell substantially as the pandemic progressed. With the original 2020 strain, about 10.4% of infected people developed long COVID. During the delta wave, that dropped to 9.5% among unvaccinated individuals and 5.3% among vaccinated ones. By the omicron era, rates fell further to 7.7% for the unvaccinated and 3.5% for the vaccinated.
Researchers attributed roughly 70% of that decline to vaccination and 30% to changes in the virus itself, along with better detection and management of the disease. Still, 3.5% is not zero. For every 100 vaccinated people who get infected, three or four develop lingering symptoms. That risk is worth factoring in, especially for people with repeated infections or underlying health conditions.
How Well the Current Vaccine Works
The 2024-2025 COVID vaccine, updated to target recent variants, provides moderate protection against hospitalization. CDC data from September 2024 through January 2025 found that for adults 65 and older without immune-compromising conditions, the vaccine reduced the risk of COVID-related hospitalization by about 45-46% during the first four months after vaccination. For immunocompromised adults in the same age group, effectiveness was around 40%.
Those numbers are lower than what most people hope for from a vaccine, but they represent a meaningful reduction in the most serious outcomes. The vaccine’s main value at this stage is keeping people out of the hospital rather than preventing infection entirely. Protection also wanes over time, which is part of why updated doses are recommended before each winter season.
Treatment Options If You Get Sick
Antiviral treatment is available for people at higher risk of severe illness. You’re generally considered a candidate if you’re over 65, unvaccinated or behind on boosters, immunocompromised, or managing multiple chronic health conditions. Treatment works best when started within the first few days of symptoms.
Cost can be a barrier, but several assistance programs exist. Medicare patients who are underinsured may be eligible for no-cost antivirals. Uninsured and underinsured individuals can access free treatment through a government patient assistance program, which is expected to continue until supplies run out or December 31, 2028, whichever comes first. Privately insured patients may also have options for reduced or eliminated cost-sharing depending on the specific treatment.
What to Actually Expect
COVID is not “coming back” in the sense of a dramatic new emergency. It’s already here, circulating at low levels, and it will rise again in a seasonal pattern that now looks fairly consistent. The practical takeaway: if you’re in a high-risk group, staying current on vaccination before the next expected wave (likely summer, then again in winter) is the single most effective thing you can do. If you get infected, early treatment is available and effective at preventing severe outcomes.
For most healthy, vaccinated adults, a COVID infection in 2026 is a manageable illness. The virus is less novel to our immune systems than it once was, treatments are accessible, and each successive wave has generally produced fewer hospitalizations and deaths than the one before. The pattern of periodic waves is likely to continue for years, much like flu seasons, but the stakes for each individual infection are considerably lower than they were at the start of the pandemic.